European stocks slipped on Friday, taking the main benchmark to its first weekly decline in three, as investors sought clarity on the pace of monetary easing in the euro zone next year amid concerns over slowing economic growth and a potential trade war.
The pan-European STOXX 600 index (.STOXX) lost 0.5% to hit a more-than one-week low and ended the week about 0.8% lower.
Stock markets have been choppy this week as investors digested stimulus updates from China, inflation data from the U.S. and euro zone as well as the European Central Bank's fourth rate cut of the year on Thursday.
Four European Central Bank policymakers backed further interest rate cuts on Friday provided that inflation settles at the ECB's 2% goal as expected. Traders are pricing in rate cuts of 112 basis points by the end of next year.
'The bar for a 50bp cut at the next meeting in January feels high, but a larger cut or cuts beyond January cannot be ruled out,' Deutsche Bank analysts said.
France's CAC 40 (.FCHI) slipped 0.1% as investors assessed whether a new government led by Francois Bayrou can tackle France's fiscal problems.
His immediate priority will be passing a special law to roll over the 2024 budget, with a nastier battle over the belt-tightening 2025 legislation looming early next year.
Healthcare stocks (.SXDP) were among top sectoral decliners, with Novo Nordisk's (NOVOb.CO), 3.9% drop, weighing the most on STOXX 600. Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's (LLY.N) Mounjaro over Novo Nordisk's Wegovy, Reuters reported based on views from online pharmacies.
U.S. stocks closed out the week little changed on Friday, ahead of a Federal Reserve policy meeting next week.
On the flip side, insurers (.SXIP) rose 1.2% and led sectoral gains as Munich Re (MUVGn.DE) climbed 5.5% after saying that it is targeting 6 billion euros ($6.27 billion) in net profit for next year, with its reinsurance business alone anticipated to make up 5.1 billion euros.
German politics were also in focus, with German Chancellor Olaf Scholz expected to hold a vote of confidence in parliament on Monday, a move that would pave the way for snap elections following the collapse of his three-way governing coalition.
The Bundesbank said Germany's economy will shrink for the second year in a row this year and its recovery will be lacklustre, potentially exacerbated by a trade war with the United States.
Despite a struggling economy, the DAX (.GDAXI) is near an all-time high, with most companies listed on the index not heavily exposed to domestic factors.
Reuters
European stocks slipped on Friday, taking the main benchmark to its first weekly decline in three, as investors sought clarity on the pace of monetary easing in the euro zone next year amid concerns over slowing economic growth and a potential trade war.
The pan-European STOXX 600 index (.STOXX) lost 0.5% to hit a more-than one-week low and ended the week about 0.8% lower.
Stock markets have been choppy this week as investors digested stimulus updates from China, inflation data from the U.S. and euro zone as well as the European Central Bank's fourth rate cut of the year on Thursday.
Four European Central Bank policymakers backed further interest rate cuts on Friday provided that inflation settles at the ECB's 2% goal as expected. Traders are pricing in rate cuts of 112 basis points by the end of next year.
'The bar for a 50bp cut at the next meeting in January feels high, but a larger cut or cuts beyond January cannot be ruled out,' Deutsche Bank analysts said.
France's CAC 40 (.FCHI) slipped 0.1% as investors assessed whether a new government led by Francois Bayrou can tackle France's fiscal problems.
His immediate priority will be passing a special law to roll over the 2024 budget, with a nastier battle over the belt-tightening 2025 legislation looming early next year.
Healthcare stocks (.SXDP) were among top sectoral decliners, with Novo Nordisk's (NOVOb.CO), 3.9% drop, weighing the most on STOXX 600. Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's (LLY.N) Mounjaro over Novo Nordisk's Wegovy, Reuters reported based on views from online pharmacies.
U.S. stocks closed out the week little changed on Friday, ahead of a Federal Reserve policy meeting next week.
On the flip side, insurers (.SXIP) rose 1.2% and led sectoral gains as Munich Re (MUVGn.DE) climbed 5.5% after saying that it is targeting 6 billion euros ($6.27 billion) in net profit for next year, with its reinsurance business alone anticipated to make up 5.1 billion euros.
German politics were also in focus, with German Chancellor Olaf Scholz expected to hold a vote of confidence in parliament on Monday, a move that would pave the way for snap elections following the collapse of his three-way governing coalition.
The Bundesbank said Germany's economy will shrink for the second year in a row this year and its recovery will be lacklustre, potentially exacerbated by a trade war with the United States.
Despite a struggling economy, the DAX (.GDAXI) is near an all-time high, with most companies listed on the index not heavily exposed to domestic factors.
Reuters
European stocks slipped on Friday, taking the main benchmark to its first weekly decline in three, as investors sought clarity on the pace of monetary easing in the euro zone next year amid concerns over slowing economic growth and a potential trade war.
The pan-European STOXX 600 index (.STOXX) lost 0.5% to hit a more-than one-week low and ended the week about 0.8% lower.
Stock markets have been choppy this week as investors digested stimulus updates from China, inflation data from the U.S. and euro zone as well as the European Central Bank's fourth rate cut of the year on Thursday.
Four European Central Bank policymakers backed further interest rate cuts on Friday provided that inflation settles at the ECB's 2% goal as expected. Traders are pricing in rate cuts of 112 basis points by the end of next year.
'The bar for a 50bp cut at the next meeting in January feels high, but a larger cut or cuts beyond January cannot be ruled out,' Deutsche Bank analysts said.
France's CAC 40 (.FCHI) slipped 0.1% as investors assessed whether a new government led by Francois Bayrou can tackle France's fiscal problems.
His immediate priority will be passing a special law to roll over the 2024 budget, with a nastier battle over the belt-tightening 2025 legislation looming early next year.
Healthcare stocks (.SXDP) were among top sectoral decliners, with Novo Nordisk's (NOVOb.CO), 3.9% drop, weighing the most on STOXX 600. Britons paying privately for obesity drugs are increasingly choosing Eli Lilly's (LLY.N) Mounjaro over Novo Nordisk's Wegovy, Reuters reported based on views from online pharmacies.
U.S. stocks closed out the week little changed on Friday, ahead of a Federal Reserve policy meeting next week.
On the flip side, insurers (.SXIP) rose 1.2% and led sectoral gains as Munich Re (MUVGn.DE) climbed 5.5% after saying that it is targeting 6 billion euros ($6.27 billion) in net profit for next year, with its reinsurance business alone anticipated to make up 5.1 billion euros.
German politics were also in focus, with German Chancellor Olaf Scholz expected to hold a vote of confidence in parliament on Monday, a move that would pave the way for snap elections following the collapse of his three-way governing coalition.
The Bundesbank said Germany's economy will shrink for the second year in a row this year and its recovery will be lacklustre, potentially exacerbated by a trade war with the United States.
Despite a struggling economy, the DAX (.GDAXI) is near an all-time high, with most companies listed on the index not heavily exposed to domestic factors.
comments